Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company's second clinical-trial flop in as many months isn't sitting well with investors.

Here's Why Theravance Biopharma Stock Is Tanking Today

Analysts have lowered the price target and downgraded Theravance Biopharma Inc (NASDAQ:TBPH) after disappointing ulcerative colitis Phase 2 trial data. Related:   Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study

Analysts Slash Price Targets After Theravance's Failed Ulcerative Colitis Study

Theravance's (TBPH) mid-stage candidate, izencitinib, fails in a study evaluating it in patients with ulcerative colitis.

Theravance (TBPH) Suffers 2nd Study Failure in Two Months

The shares of Theravance Biopharma Inc (NASDAQ: TBPH) fell by over 25% pre-market. This is why it happened.

Theravance Biopharma Shares Fall Over 25% Pre-Market: Why It Happened

Theravance Biopharma Inc's (NASDAQ: TBPH) Izencitinib, a "gut-selective" JAK inhibitor developed for ulcerative colitis and Crohn's disease, failed a key Phase 2 trial. Johnson & Johnson's (NYSE: JNJ) pharmaceutical unit Janssen dished out $100 million upfront in a partnership with Theravance to develop Izencitinib back in 2018.

Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study

Shares of Theravance Biopharma Inc. TBPH, +0.85% fell more than 20% in the extended session Monday after the biopharmaceutical company said that a dose-finding study of one of its drugs, izencitinib, didn't measure up to a placebo in the treatment of ulcerative colitis. The company said it will look at the data to better understand findings and potential for the drug.

Theravance Bio stock falls more than 20% after drug trial disappoints

DUBLIN and SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, today announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis.

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

Theravance's (TBPH) loss narrows in the second quarter of 2021 while revenues decline year over year. Stock up.

Theravance's (TBPH) Q2 Earnings Beat, Pipeline On Track

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q2 2021 Results - Earnings Call Transcript

Shares of Theravance Biopharma (NASDAQ:TBPH) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 20.00% year over year to ($0.80), which beat the estimate of ($1.01).

Recap: Theravance Biopharma Q2 Earnings

DUBLIN, Aug. 3, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter of 2021. "We made strong progress in the second quarter.

Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

DUBLIN, Ireland, July 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2021 financial results and provide a business update after market close on Tuesday, August 3, 2021. An accompanying conference call and simultaneous webcast will be hosted at 5:00 p.m.

Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021

DUBLIN, June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the pricing of its underwritten public offering of 6,700,000 ordinary shares at a price to the public of $15.00 per share. The gross proceeds to Theravance Biopharma from the offering are expected to be $100.5 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares

DUBLIN, June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today that it intends to offer its ordinary shares in an underwritten public offering. Theravance Biopharma also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares in the offering.

Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares

Theravance's (TBPH) JAK inhibitor candidate, nezulcitinib, fails to achieve statistically significant improvement in the number of respiratory failure-free days in hospitalized COVID-19 patients with lung injury.

Theravance (TBPH) COVID-19 Therapy Fails in Mid-Stage Study

Theravance Biopharma Inc (NASDAQ: TBPH) has announced top-line results from its Phase 2 study evaluating nezulcitinib for hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation.  Nezulcitinib is an investigational, inhaled, lung-selective, pan-Janus kinase (JAK) inhibitor.

Theravance Biopharma Stock Drops After Nezulcitinib Disappoints In COVID-19 Study

DUBLIN and SOUTH SAN FRANCISCO, Calif., June 21, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, today announced top-line results from its Phase 2 study of 3 mg once-daily nezulcitinib compared to placebo, each in combination with standard of care.

Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Theravance Bio (TBPH) Down 13% Since Last Earnings Report: Can It Rebound?

American Woodmark

Arena Pharmaceuticals

Atreca

Cannae Hlds

Dominion Energy

ESCO Technologies

FutureFuel

Heartland Express

Intelligent Systems

Kiniksa Pharmaceuticals Ltd

Kura Oncology

Madrigal Pharmaceuticals

NewMarket

PG&E

Premier

SelectQuote

Invesco DB US Dollar Index Bullish Fund

Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since March.

20 Short Ideas With Super-Weak Momentum

Theravance's (TBPH) loss narrows in the first quarter of 2021 while revenues decline year over year.

Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q1 2021 Results - Earnings Call Transcript

Shares of Theravance Biopharma (NASDAQ:TBPH) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 8.77% over the past year to ($1.24), which missed the estimate of ($1.05).

Theravance Biopharma: Q1 Earnings Insights

DUBLIN, May 4, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter of 2021. "2021 is on track to be a transformational year as we make significant progress towards our business goals," said Rick E Winningham, Chief Executive Officer.

Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

DUBLIN, April 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its first quarter 2021 financial results and provide a business update after market close on Tuesday, May 4, 2021. An accompanying conference call and simultaneous webcast will be hosted at 5:00 p.m.

News for Theravance Biopharma Stock (TBPH)